PHILADELPHIA, Aug. 12, 2025 /PRNewswire/ -- Berger Montague PC is investigating potential securities fraud claims on behalf of investors of CTO Realty Growth, Inc. (NYSE: CTO) ("CTO" or the "Company") following the filing of a securities class action lawsuit on behalf of investors who purchased or otherwise acquired CTO securities between February 18, 2021 through June 24, 2025 (the "Class Period").Investor Deadline: Investors who purchased or acquired CTO securities during the Class Period may, no later th ...

The U.S. Food and Drug Administration (FDA) on Tuesday approved Insmed Incorporated’s INSM Brinsupri (brensocatib 10 mg and 25 mg tablets). It is an oral, once-daily treatment for non-cystic fibrosis bronchiectasis (NCFB) in adults and children 12 years and older.Brinsupri is the first and only FDA-approved treatment for NCFB, a chronic lung condition characterized by permanently widened and damaged airways (bronchi), leading to persistent mucus production, recurrent infections, and difficulty breathing.The ...

Key Takeaways Metal Cutting and Infrastructure segments saw Q4 2025 organic sales fall 4% and 5%, respectively.Long-term debt stood at $596.8M, with cash holdings of $140.5M at fiscal year-end.Fiscal 2026 EPS estimate fell from $1.38 to $1.22 over the past 60 days.Kennametal Inc. (KMT) has failed to impress investors with its recent operational performance due to weakness across its businesses and high debt level.Based in Pittsburgh, PA, Kennametal is engaged in designing, manufacturing and marketing high-s ...

Key Takeaways CWCO Q2 EPS rose to 32 cents, beating estimates by 60% and up 23.1% year over year.Revenues climbed 6.3% to $33.6M, led by gains in Retail and Manufacturing segments.Grand Cayman retail sales rose 7% on lower rainfall, population growth and higher activity.Consolidated Water Co. Ltd. (CWCO) delivered second-quarter 2025 earnings per share (EPS) of 32 cents, which beat the Zacks Consensus Estimate of 20 cents by 60%.The bottom line also improved 23.1% compared with the year-ago period’s earning ...

Key Takeaways MMM's Transportation and Electronics segment adjusted organic revenues grew 1% in Q2 2025.Growth was driven by strength in aerospace, defense, auto and commercial graphics markets.Consumer electronics softness and weak auto build rates in the US and Europe remain challenges.3M Company’s (MMM) Transportation and Electronics segment is experiencing a challenging yet gradually improving demand environment. In the second quarter of 2025, the segment’s adjusted organic revenues increased 1% year ov ...

Sea has re-emerged as a growth all-star after a long hangover after the early days of the COVID pandemic.Shares of Southeast Asian super-app company Sea Limited (SE 19.63%) had rocketed 20.5% higher on Tuesday as of 12:30 p.m.Sea reported earnings this morning that, while missing estimates on the bottom line, trounced estimates for revenue growth, with strength across all three of its businesses. As a high-growth stock, that top-line strength appears to be what investors care about most. Sea fires on all cy ...

Ford Motor Company F unveiled a Universal EV Platform for a midsize electric truck, highlighting simpler construction, streamlined manufacturing, and a structural battery for greater efficiency.Goldman Sachs analyst Mark Delaney reiterated the Neutral rating on Ford Motor, with a price forecast of $11.After attending Ford's Universal EV Platform event in Louisville, Delaney said the first application will be a midsize BEV truck priced around $30,000, with deliveries in 2027.Also Read: Clearwater Analytics G ...

Core Viewpoint - Enphase Energy, Inc. (ENPH) has experienced a significant decline in its stock price, losing 28.2% over the past three months, underperforming both the solar industry and broader market indices [1][8]. Performance Comparison - Other solar stocks, such as Canadian Solar (CSIQ) and SolarEdge Technologies (SEDG), have shown strong performance, with CSIQ gaining 14.1% and SEDG gaining 37.2% in the same period [2]. Factors Behind Weak Performance - ENPH's stock decline is attributed to weak demand, particularly in Europe, where international sales fell due to lower utility rates and policy changes [4]. - Higher production costs, driven by new U.S. tariffs on imports and reduced tax credits for residential solar projects under the One Big Beautiful Bill Act, have further pressured profits [5]. Future Outlook - Enphase Energy is expanding its global footprint with shipments of its IQ8P microinverter to various countries and plans to launch the next-generation IQ9 microinverter [6][9]. - The company is also enhancing its battery storage segment with new products aimed at increasing energy density and reducing costs [6]. Financial Position - As of June 30, 2025, Enphase Energy reported cash and cash equivalents of $1.53 billion, with long-term debt at $0.57 billion and current debt at $0.63 billion, indicating a solid solvency position [10]. - The company has repurchased shares worth approximately $130 million in the first half of 2025, with an additional $268.7 million authorized for buybacks [10]. Revenue and Earnings Estimates - The Zacks Consensus Estimate indicates an 8.6% improvement in ENPH's 2025 revenues compared to the previous year, with positive earnings growth expected [11]. - Current estimates for the upcoming quarters show a decline in year-over-year growth for the current quarter and next quarter, but an overall improvement for the current year [12][13]. Valuation Metrics - ENPH shares are trading at a trailing 12-month Price/Sales (P/S TTM) ratio of 2.97, which is higher than the industry average of 1.86 [14]. - In comparison, peers CSIQ and SEDG are trading at significantly lower P/S TTM ratios of 0.13 and 1.55, respectively [16].

Group 1: Company Performance - Honeywell International Inc. (HON) is experiencing strong momentum in its Building Automation segment, driven by solid demand for products and solutions, particularly in North America and the Middle East [1][2] - The Building Automation segment's organic sales increased by 8% year over year in Q2 2025, with building products sales growing by 9% and building solutions sales improving by 5% [2][8] - Overall backlog for Honeywell grew by 10% year over year to $36.6 billion, with expectations for overall revenues in 2025 to be in the range of $40.8-$41.3 billion, reflecting a 4-5% organic revenue increase [4] Group 2: Market Trends and Projections - The company anticipates that the Building Automation segment's organic sales will grow in the mid to high-single digits for 2025, supported by software-led new product introductions and customer wins in focused verticals [3][8] - Honeywell's shares have gained 10% over the past year, outperforming the industry's growth of 1.6% [7] Group 3: Peer Comparison - Among peers, Carlisle Companies Incorporated (CSL) reported a 0.6% year-over-year revenue increase in its Construction Materials segment, driven by strong demand for reroofing products [5] - 3M Company (MMM) saw a 2.5% year-over-year organic sales growth in its Safety and Industrial segment, supported by stable demand in various markets [6] Group 4: Valuation and Earnings Estimates - Honeywell is currently trading at a forward price-to-earnings ratio of 19.64X, above the industry average of 16.33X, and carries a Value Score of D [10] - The Zacks Consensus Estimate for Honeywell's 2025 earnings has been on the rise over the past 60 days, with current estimates for the current year at $10.49 and next year at $11.36 [12][13]

Core Insights - The AGA-sponsored survey conducted by The Harris Poll reveals that IBS symptoms disrupt patients' productivity and personal activities for an average of 19 days each month, significantly affecting both personal and professional life [1][2] Patient Impact - IBS symptoms interfere with productivity at work or school for nearly 11 days per month on average, in addition to disrupting personal activities for eight days per month [3] - Patients are missing more work or school days due to gastrointestinal symptoms than they were a decade ago, with an increase from 2.1 days in 2015 to 3.6 days in 2024 [3] - A significant percentage of patients (58%) report spending less time with family and friends due to their symptoms, an increase from 48% in 2015 [3] Symptom Management - While fewer patients report their symptoms as very or extremely bothersome (43% in 2024 compared to 62% in 2015), 76% still find it somewhat or very difficult to manage their symptoms [4] - Less than one in three patients (31% in 2024) can accurately predict whether they will experience symptoms on a given day, consistent with 29% in 2015 [4] Emotional and Social Effects - A significant number of patients (72%) do not feel like themselves due to their symptoms, and 69% feel their symptoms prevent them from reaching their full potential [6] - The survey highlights that IBS continues to challenge patients in making plans and impacts their self-perception [5] Treatment Landscape - Despite advancements in treatment options over the last decade, patients and healthcare providers predominantly rely on over-the-counter treatments and lifestyle adjustments rather than prescription medications [7] - Among patients who have tried prescription medications, only 18% for IBS-C and 19% for IBS-D find them among the most helpful treatments [8] - The most common recommendations from healthcare providers include avoiding situations with limited bathroom access (77%) and difficulty in planning due to unpredictable symptoms (72%) [8] Provider-Patient Interaction - Approximately 45% of healthcare providers say they will recommend or prescribe a specific IBS treatment requested by patients, but only about 14% of patients often make such requests [9] - Most patients with IBS-C and IBS-D (78% each) are satisfied with their current treatments, but only about 25% for IBS-C and 26% for IBS-D are very satisfied [10] Opportunities for Improvement - Compared to 2015, more physicians report that effective relief of abdominal pain (49% vs. 39%) and the availability of treatment options (49% vs. 34%) are lacking in IBS treatment today [10] - The findings indicate a need for further improvement in treatment efficacy and patient satisfaction [10]